Shares of C4 Therapeutics Inc. (CCCC) have plummeted 51% from their 52-week high of $11.38, reached in March, and trade around $5. As the company prepares for an upcoming data readout next month, it may be prudent to revisit the stock.
C4 Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of small-molecule medicines based on its proprietary technology platform, TORPEDO (Target ORiented ProtEin Degrader Optimizer). Its clinical pipeline includes Cemsidomide, formerly known as CFT7455, and CFT1946.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.